Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
Vo Van Giau,1,* Hyon Lee,2,* Kyu Hwan Shim,1 Eva Bagyinszky,1 Seong Soo A An1 1Department of Bionano Technology, Gachon University, Seongnam, South Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South Korea *These authors contributed equally to this work Abstract:...
Guardado en:
Autores principales: | Giau VV, Lee H, Shim KH, Bagyinszky E, An SSA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/95bdeabb3b314e69a3cf6babb7dda1da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bioinformational analysis of Yersinia pseudotuberculosis IP32953 CRISPR/cas system
por: N. P. Peretolchina, et al.
Publicado: (2016) -
CRISPR and KRAS: a match yet to be made
por: Guzide Bender, et al.
Publicado: (2021) -
A pathogenic PSEN2 p.His169Asn mutation associated with early-onset Alzheimer’s disease
por: Giau VV, et al.
Publicado: (2018) -
Disabling a Type I-E CRISPR-Cas Nuclease with a Bacteriophage-Encoded Anti-CRISPR Protein
por: April Pawluk, et al.
Publicado: (2017) -
Characterization of a Type II-A CRISPR-Cas System in <italic toggle="yes">Streptococcus mutans</italic>
por: Cas Mosterd, et al.
Publicado: (2020)